Howard Mayer

Howard Mayer currently works at Autism Speaks, Inc., as Director from 2011, Melmark Charitable Foundation, as Director from 2016, PepGen Inc., as Independent Non-Executive Director from 2023, and Ipsen Pharmaceuticals, Inc., as Executive VP, Head-Research & Development from 2019.
Dr. Mayer also formerly worked at Bristol Myers Squibb Co., as Director-Infectious Diseases Clinical Research, Genocea Biosciences, Inc., as Independent Director from 2017 to 2020, Entasis Therapeutics Holdings, Inc., as Independent Director from 2019 to 2022, Invivyd, Inc., as Independent Director from 2020 to 2022, Pfizer Inc., as Head-Clinical Development & Medical Affairs from 2002 to 2009, Ipsen SA, as Executive Vice President-Research & Development from 2019 to 2023, EMD Serono, Inc., as Chief Medical Officer from 2009 to 2012, Takeda Pharmaceuticals U.S.A., Inc., as Head-Rare Disease Business Unit, R&D, Shire Pharmaceuticals, Inc., as Chief Medical Officer & Senior Vice President from 2018 to 2019, and Ipsen Biopharmaceuticals, Inc., as Executive VP, Head-Research & Development from 2019 to 2023.
Dr. Mayer received his undergraduate degree from the University of Pennsylvania and doctorate degree from Albert Einstein College of Medicine, Inc.